|
1
|
Whelan JS and Davis LE: Osteosarcoma,
chondrosarcoma, and chordoma. J Clin Oncol. 36:188–193. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schiavone K, Garnier D, Heymann MF and
Heymann D: The heterogeneity of osteosarcoma: The role played by
cancer stem cells. Adv Exp Med Biol. 1139:187–200. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brown HK, Tellez-Gabriel M and Heymann D:
Cancer stem cells in osteosarcoma. Cancer Lett. 386:189–195. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan GN, Lv YF and Guo QN: Advances in
osteosarcoma stem cell research and opportunities for novel
therapeutic targets. Cancer Lett. 370:268–274. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Clevers H: The cancer stem cell: Premises,
promises, and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shackleton M, Quintana E, Fearon ER and
Morrison SJ: Heterogeneity in cancer: Cancer stem cells versus
clonal evolution. Cell. 138:822–829. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujiwara T, Katsuda T, Hagiwara K, Kosaka
N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T,
Ichikawa H, et al: Clinical relevance and therapeutic significance
of microRNA-133a expression profiles and functions in malignant
osteosarcoma-initiating cells. Stem Cells. 32:959–973. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Honoki K, Fujii H, Kubo A, Kido A, Mori T,
Tanaka Y and Tsujiuchi T: Possible involvement of stem-like
populations with elevated ALDH1 in sarcomas for chemotherapeutic
drug resistance. Oncol Rep. 24:501–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Adhikari AS, Agarwal N, Wood BM, Porretta
C, Ruiz B, Pochampally RR and Iwakuma T: CD117 and Stro-1 identify
osteosarcoma tumor-initiating cells associated with metastasis and
drug resistance. Cancer Res. 70:4602–4612. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tian J, Li X, Si M, Liu T and Li J: CD271+
osteosarcoma cells display stem-like properties. PLoS One.
9:e985492014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qi XT, Li YL, Zhang YQ, Xu T, Lu B, Fang
L, Gao JQ, Yu LS, Zhu DF, Yang B, et al: KLF4 functions as an
oncogene in promoting cancer stem cell-like characteristics in
osteosarcoma cells. Acta Pharmacol Sin. 40:546–555. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee YH, Yang HW, Yang LC, Lu MY, Tsai LL,
Yang SF, Huang YF, Chou MY, Yu CC and Hu FW: DHFR and MDR1
upregulation is associated with chemoresistance in osteosarcoma
stem-like cells. Oncol Lett. 14:171–179. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dong J, Bi B, Zhang L and Gao K: GLIPR1
inhibits the proliferation and induces the differentiation of
cancer-initiating cells by regulating miR-16 in osteosarcoma. Oncol
Rep. 36:1585–1591. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qu H, Xue Y, Lian W, Wang C, He J, Fu Q,
Zhong L, Lin N, Lai L, Ye Z and Wang Q: Melatonin inhibits
osteosarcoma stem cells by suppressing SOX9-mediated signaling.
Life Sci. 207:253–264. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maloney A and Workman P: HSP90 as a new
therapeutic target for cancer therapy: The story unfolds. Expert
Opin Biol Ther. 2:3–24. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Neckers L: Hsp90 inhibitors as novel
cancer chemotherapeutic agents. Trends Mol Med. 8 (4
Suppl):S55–S61. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barker CR, Hamlett J, Pennington SR,
Burrows F, Lundgren K, Lough R, Watson AJ and Jenkins JR: The
topoisomerase II-Hsp90 complex: A new chemotherapeutic target? Int
J Cancer. 118:2685–2693. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
White PT, Subramanian C, Zhu Q, Zhang H,
Zhao H, Gallagher R, Timmermann BN, Blagg BS and Cohen MS: Novel
HSP90 inhibitors effectively target functions of thyroid cancer
stem cell preventing migration and invasion. Surgery. 159:142–152.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim HB, Lee SH, Um JH, Kim MJ, Hyun SK,
Gong EJ, Oh WK, Kang CD and Kim SH: Sensitization of
chemo-resistant human chronic myeloid leukemia stem-like cells to
Hsp90 inhibitor by SIRT1 inhibition. Int J Biol Sci. 11:923–934.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nanta R, Shrivastava A, Sharma J, Shankar
S and Srivastava RK: Inhibition of sonic hedgehog and PI3K/Akt/mTOR
pathways cooperate in suppressing survival, self-renewal and
tumorigenic potential of glioblastoma-initiating cells. Mol Cell
Biochem. 454:11–23. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kobune M, Takimoto R, Murase K, Iyama S,
Sato T, Kikuchi S, Kawano Y, Miyanishi K, Sato Y, Niitsu Y and Kato
J: Drug resistance is dramatically restored by hedgehog inhibitors
in CD34+ leukemic cells. Cancer Sci. 100:948–955. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee
HJ, Kim TS, Janjigian YY, Cohen DJ and Yoon SS: CD44 expression
denotes a subpopulation of gastric cancer cells in which Hedgehog
signaling promotes chemotherapy resistance. Clin Cancer Res.
20:3974–3988. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mastrangelo E and Milani M: Role and
inhibition of GLI1 protein in cancer. Lung Cancer (Auckl). 9:35–43.
2018.PubMed/NCBI
|
|
26
|
Pan Y, Shu X, Sun L, Yu L, Sun L, Yang Z
and Ran Y: miR-196a-5p modulates gastric cancer stem cell
characteristics by targeting Smad4. Int J Oncol. 50:1965–1976.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmittgen TD, Zakrajsek BA, Mills AG,
Gorn V, Siner MJ and Reed MW: Quantitative reverse transcription
polymerase chain reaction to study mRNA decay: Comparison of end
point and realtime methods. Anal Biochem. 285:194–204. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martins-Neves SR, Paiva-Oliveira DI,
Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovee JV,
Cleton-Jansen AM and Gomes CM: Chemotherapy induces stemness in
osteosarcoma cells through activation of Wnt/β-catenin signaling.
Cancer Lett. 370:286–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu L, Fan Z, Fang S, Yang J, Gao T, Simoes
BM, Eyre R, Guo W and Clarke RB: Cisplatin selects for stem-like
cells in osteosarcoma by activating notch signaling. Oncotarget.
7:33055–33068. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Trnski D, Sabol M, Gojević A, Martinić M,
Ozretić P, Musani V, Ramić S and Levanat S: GSK3β and Gli3 play a
role in activation of Hedgehog-Gli pathway in human colon
cancer-Targeting GSK3β downregulates the signaling pathway and
reduces cell proliferation. Biochim Biophys Acta. 1852:2574–2584.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Izadpanah S, Shabani P, Aghebati-Maleki A,
Baghbanzadeh A, Fotouhi A, Bisadi A, Aghebati-Maleki L and
Baradaran B: Prospects for the involvement of cancer stem cells in
the pathogenesis of osteosarcoma. J Cell Physiol. 235:4167–4182.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu B, Ma W, Jha RK and Gurung K: Cancer
stem cells in osteosarcoma: Recent progress and perspective. Acta
Oncol. 50:1142–1150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Basu-Roy U, Basilico C and Mansukhani A:
Perspectives on cancer stem cells in osteosarcoma. Cancer Lett.
338:158–167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sauvageot CM, Weatherbee JL, Kesari S,
Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung
AL, Kieran MW and Wen PY: Efficacy of the HSP90 inhibitor 17-AAG in
human glioma cell lines and tumorigenic glioma stem cells. Neuro
Oncol. 11:109–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Newman B, Liu Y, Lee HF, Sun D and Wang Y:
HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells.
Cancer Res. 72:4551–4561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Amini S, Fathi F, Mobalegi J,
Sofimajidpour H and Ghadimi T: The expressions of stem cell
markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3,
Dppa4, and Esrrb in bladder, colon, and prostate cancer, and
certain cancer cell lines. Anat Cell Biol. 47:1–11. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sarto C, Binz PA and Mocarelli P: Heat
shock proteins in human cancer. Electrophoresis. 21:1218–1226.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Staufer K and Stoeltzing O: Implication of
heat shock protein 90 (HSP90) in tumor angiogenesis: A molecular
target for anti-angiogenic therapy? Curr Cancer Drug Targets.
10:890–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zuehlke A and Johnson JL: Hsp90 and
co-chaperones twist the functions of diverse client proteins.
Biopolymers. 93:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao Z, Jia Q, Wu MS, Xie X, Wang Y, Song
G, Zou CY, Tang Q, Lu J, Huang G, et al: Degalactotigonin, a
natural compound from solanum nigrum L., inhibits growth and
metastasis of osteosarcoma through GSK3β inactivation-mediated
repression of the hedgehog/Gli1 pathway. Clin Cancer Res.
24:130–144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stecca B, Mas C, Clement V, Zbinden M,
Correa R, Piguet V, Beermann F and Ruiz I Altaba A: Melanomas
require HEDGEHOG-GLI signaling regulated by interactions between
GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA.
104:5895–5900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG,
Lang JY, Li CW, Hsu JL, Miller SA, Wang X, et al: The crosstalk of
mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 21:374–387. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Das S, Harris LG, Metge BJ, Liu S, Riker
AI, Samant RS and Shevde LA: The hedgehog pathway transcription
factor GLI1 promotes malignant behavior of cancer cells by
up-regulating osteopontin. J Biol Chem. 284:22888–22897. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jiang J and Hui CC: Hedgehog signaling in
development and cancer. Dev Cell. 15:801–812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ruiz I Altaba A: Gli proteins and Hedgehog
signaling: Development and cancer. Trends Genet. 15:418–425. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ng JM and Curran T: The Hedgehog's tale:
Developing strategies for targeting cancer. Nat Rev Cancer.
11:493–501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Katoh Y and Katoh M: Integrative genomic
analyses on GLI1: Positive regulation of GLI1 by Hedgehog-GLI,
TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of
GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol.
35:187–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tang QL, Xie XB, Wang J, Chen Q, Han AJ,
Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase
kinase-3β, NF-KB signaling, and tumorigenesis of human
osteosarcoma. J Nat Cancer Inst. 104:749–63. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hur EM and Zhou FQ: GSK3 signaling in
neural development. Nat Rev Neurosci. 11:539–551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Beurel E, Grieco SF and Jope RS: Glycogen
synthase kinase-3 (GSK3): Regulation, actions, and diseases.
Pharmacol Ther. 148:114–131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Riobó NA, Lu K, Ai X, Haines GM and
Emerson CP Jr: Phosphoinositide 3-kinase and Akt are essential for
Sonic Hedgehog signaling. Proc Natl Acad Sci USA. 103:4505–4510.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Feng X, Xu W, Li Z, Song W, Ding J and
Chen X: Immunomodulatory Nanosystems. Adv Sci (Weinh).
6:19001012019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yin F, Wang Z, Jiang Y, Zhang T, Wang Z,
Hua Y, Song Z, Liu J, Xu W, Xu J, et al: Reduction-responsive
polypeptide nanomedicines significantly inhibit progression of
orthotopic osteosarcoma. Nanomedicine. 23:1020852020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ding J, Chen J, Gao L, Jiang Z, Zhang Y,
Li M, Xiao Q, Lee SS and Chen X: Engineered nanomedicines with
enhanced tumor penetration. Nano Today. 29:1008002019. View Article : Google Scholar
|
